Apimeds Pharmaceuticals US (APUS) earnings, Jul 28, 2026: EPS −205%, stock +27.2%
In brief
Apimeds Pharmaceuticals US reported on Jul 28, 2026. Earnings per share changed −205% year over year, 0.0% above the estimate; revenue 0%. The stock opened with a +5.9% gap and closed the day +27.2% (Jul 28, 2026). The stock is now 93.2% below its 52-week high, −90.0% over 12 months.
EPS vs estimate0.0%
EPS, YoY−205%
Revenue, YoY0%
Gap · day+5.9% · +27.2%
EPS growth by quarter, YoY
Price reaction to earnings
| Report | Gap | Day |
|---|---|---|
| Apr 28, 2026 | 0.0% | 0.0% |
| Jul 28, 2026 | +5.9% | +27.2% |
Next-quarter estimates, ratings and the APUS chart are in the terminal.
Open the terminalFAQ
When is Apimeds Pharmaceuticals US's next earnings report?
There is no new date in the data yet: companies announce it a few weeks ahead.
How did Apimeds Pharmaceuticals US stock react to the report?
Opening gap +5.9%, day's result +27.2%.
Did Apimeds Pharmaceuticals US's earnings grow?
Earnings per share fell 205% year over year.
What is an earnings gap?
The jump between the close before and the open after the report. A big gap up often means large buyers are revaluing the company.